The trademark application Thalidomide BMS was filed by Bristol-Myers Squibb Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on October 6, 2022, and it was registered by office on January 13, 2023 without any oppositions.
The application was filed in English (French was selected as the second language).
Change of name and professional address of the trademark registration was recorded on January 11, 2024.